Living Cell Technologies NTCell meets primary endpoint in Phase I/IIa Parkinson’s trial

Living Cell Technologies (ASX:LCT) touted data today showing its NTCell cell therapy is safe 130 weeks after treatment in a Phase I/IIa Parkinson’s trial. The study’s primary endpoint was safety.

The trial, which enrolled and treated 4 patients, involved implanting 40 NTCell capsules into 1 side of the brain. The company reported that treatment with NTCell continues to show improvement in motor function in patients with Parkinson’s disease, as measured by the Unified Parkinson’s Disease Rating Scale.

Get the full story at our sister site, Drug Delivery Business News.

The post Living Cell Technologies NTCell meets primary endpoint in Phase I/IIa Parkinson’s trial appeared first on MassDevice.

from MassDevice http://ift.tt/2sO1OPl